3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Carcinoma, Transitional Cell
9
Carcinoma, Renal Cell
8
Colorectal Neoplasms
7
Urinary Bladder Neoplasms
6
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
3
Glioblastoma
3
Carcinoma, Neuroendocrine
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Neuroendocrine Tumors
2
Kidney Neoplasms
2
Kidney Diseases
2
Head and Neck Neoplasms
2
Glioma
2
Fallopian Tube Neoplasms
2
Carcinoma, Merkel Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Testicular Neoplasms
1
Testicular Diseases
1
Interventions
avelumab
1
Cystectomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Non-metastatic Muscle Invasive Bladder Cancer
×
avelumab
×
Clear all
NCT03674424
2025-02-26
AURA
Jules Bordet Institute
Phase 2
Completed
137 enrolled